MESA LABORATORIES INC /CO/ (MLAB) Form 10-Q — Aug 10, 2026
Mesa Laboratories reported fiscal Q1 2027 revenue of $60.1 million for the quarter ended June 30, 2026, up 1.0% year over year, while operating income more than doubled to $7.0 million from $3.1 million on gross margin expansion to 64.9% and a 5.6% cut in operating expenses. Diluted EPS fell to $0.49 from $0.85, primarily because a prior-year ~$6.1 million foreign currency gain did not repeat and interest expense rose after refinancing the 1.375% convertible notes with credit facility borrowings.
Key figures
- Eps
- 0.49
- Revenue
- 60138000
- Net Income
- 2830000
- Revenue Yoy
- 1.0%
- Cash Position
- 30695000
- Shares Outstanding
- 5595869
- Gross Margin
- 64.9%
- Working Capital
- 45500000
- Operating Income
- 7031000
- Revolver Balance
- 77250000
- Dividend Per Share
- 0.16
- Effective Tax Rate
- 35.0%
- Operating Cash Flow
- 14736000
- Revolver Available
- 47750000
- Diluted Eps Prior Year
- 0.85
- Debt Reduced In Quarter
- 8700000
- Gross Margin Prior Year
- 62.0%
- Credit Facility Maturity
- April 2029
- Weighted Avg Interest Rate
- 5.6%
- Operating Income Prior Year
- 3064000
- Operating Cash Flow Prior Year
- 1893000
- Term Loan Principal Remaining
- 66094000
- Expected Cash Interest Next12 Months
- 7900000
Price after filing
Close on the filing date to close N calendar days later (from $102.65). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.